A Worthwhile Exit StrategyETF Trends · 13 hr ago
AbbVie Inc. $ABBV Stock: Evergreen Capital Management LLC Grows StakeDefense World · 15 hr ago
U.S. FDA Approves Subcutaneous Induction Regimen for AbbVie's SKYRIZI® (risankizumab-rzaa) for Adults With Moderately to Severely Active Crohn's DiseaseGuruFocus · 2 days ago
U.S. FDA Approves Subcutaneous Induction Regimen for AbbVie's SKYRIZI® (risankizumab-rzaa) for Adults With Moderately to Severely Active Crohn's DiseasePRNewsWire · 2 days ago
AbbVie's Dividend Survived Humira's Patent Cliff. Will Merck and Amgen's?24/7 Wall Street · 2 days ago
Forget Chasing 7% Yields: These 5 Dividend Stocks Offer Something Different24/7 Wall Street · 2 days agoAbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
| Date | Est. | Actual | |
|---|---|---|---|
| Jul 31, 2026 | $3.61 | $3.65 | Beat |
| Apr 29, 2026 | $2.59 | $2.65 | Beat |
| Feb 4, 2026 | $2.65 | $2.71 | Beat |
| Oct 31, 2025 | $1.77 | $1.86 | Beat |
| Jul 31, 2025 | $2.88 | $2.97 | Beat |
| Apr 25, 2025 | $2.38 | $2.46 | Beat |